A Non St Elevation Acute Coronary Syndrome

1200 Words Nov 1st, 2015 5 Pages
In the management of an NSTE-ACS patient who underwent early PCI, is there any distinction between Plavix and Brilinta in reducing thrombotic CV events?

Lucia A. Garza

Master’s Project

Submitted in Partial Fulfillment of the
Requirements for the
Degree of:
Masters in Physician Assistant Studies

University of Texas Rio Grande Valley
College of Health Sciences & Human Services
Department of Physician Assistant Studies
Edinburg, Texas

December 2015

A non-ST elevation acute coronary syndrome (NSTE-ACS) is a very common presentation to emergency departments everywhere, as well as primary care practices. Therefore, it is important that all providers be well informed on the effectivity of certain treatment regimens. According to guidelines stipulated by the American Heart Association (AHA) Plavix (clopidogrel) and aspirin (ASA) have been the mainstay of antiplatelet therapy post ACS. However, with the development of newer antiplatelet medications, guidelines have been adjusted to reflect these changes. Ticagrelor, trade name Brilinta, is a relatively new oral P2Y12 inhibitor that could also be used post NSTE-ACS and post percutaneous intervention (PCI).3 Therefore, this manuscript will investigate the efficacy of Brilinta versus Plavix in an NSTE-ACS patient that underwent early PCI.
Most of the journal articles used in this manuscript were accessed under the University of Texas Rio Grande Valley Library website (www.utpa.edu/library). Over 54 journal…
Open Document